Related Experiment Video
Updated: Aug 12, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
[Dermatology - Update on systemic treatments for locally advanced and/or metastatic cutaneous squamous cell
1Unité de dermato-oncologie, Service de dermatologie et vénéréologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Abstract:
Cutaneous squamous cell carcinoma (cSCC) is a common skin malignancy successfully treated by surgery in most patients. Locally advanced (la) and/or metastatic (m) cSCC require systemic treatments to either achieve complete remission or local control before subsequent surgery or radiotherapy. Recently, monoclonal antibodies against programmed cell death protein-1 (PD-1) have proven to be effective in several la/m cSCC treatment trials, with response rates up to 45 % and a one-year progression-free survival up to 55 %. Very recently, the use of anti-PD-1 as a neoadjuvant therapy was evaluated and resulted in a pathological response in almost two-thirds of tumors subsequently removed.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

